MedTrace Logo

Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL

NCT01225874 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3762

Last updated 2016-02-23

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood or bone marrow from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This trial is studying biomarkers to classify young patients with acute lymphoblastic leukemia (ALL) and remission induction therapy in young patients with B-precursor ALL.

Conditions

Interventions

DRUG

SC-PEG E. coli L-asparaginase

Given IM

DRUG

cytarabine

Given IT

DRUG

daunorubicin hydrochloride

Given IV

DRUG

dexamethasone

Given orally

DRUG

methotrexate

Given IT

DRUG

pegaspargase

Given IM

DRUG

prednisone

Given orally

DRUG

vincristine sulfate

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Dale J. Pullen, MD · University of Mississippi Cancer Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-12-31
Primary Completion
2006-03-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01225874 on ClinicalTrials.gov